Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Aug
04
Today In Oncology
Next-Generation Sequencing Uptake Remains Low Among Medicare Beneficiaries, Study Finds
U.S. News & World Report Announces 2026–2027 Best Cancer Hospitals
TOPAZ-1 Post Hoc Analysis Supports Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer
FDA Approves Radionuclide Therapy Plus ARPI for mAPMN/S Prostate Cancer
Quantum Machine Learning Framework Improves Prediction of Antigen Presentation and Immunotherapy Response
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo